Abstract 2702
Background
As an ESMO designated centre of integrated oncology and palliative care it is important to have a range of skill mix and experience across the oncology nursing staff caring for these patients. Within a large acute general hospital, with patients on various wards across the hospital, challenges in achieving these aims may present themselves. The core ward consists of 14 single rooms; the non-core wards have a mix of 1, 2, 4 and 6 bedded rooms. This analysis aimed to assess the nature of hospitalisations and the associated outcomes for the whole cohort of patients on the associated ward.
Methods
All inpatients who were admitted or were pre-existing patients during the period of 8 weeks of analysis were assessed. The main features considered were the age, gender, cancer diagnosis, co-morbidities, reason for admission, and whether they returned to home, hospice or died in hospital. Whether patients were on the core chemotherapy ward or on outlying wards was assessed. Data from retrieved from the medical and nursing handover records and clinical information system of the Hospital.
Results
There were 44 patients (37.8%) cared for over the 50 admissions on the Core Therapeutic Ward staffed by oncology nurses over the 8 week period with the remainder cared for over the 92 admissions on outlying wards staffed by non-oncology nurses. The three most common reasons for admission (core/non-core ward) included symptom management with disease progression (42% vs 50%), anti-cancer therapy associated toxicities (18% vs 13%) & decline in activities of daily living (16% vs 15%). The most common oncology primary cancers included CNS (25% vs 20%), Lower GI (16% vs 15%) and GU (11.4% vs 13.5%). Disease related impaired cognition was the most common baseline co-morbidity present in each cohort (27.3%/12.2%). The patient discharge outcomes on each ward (onc/non-onc) were home (56.8%/85.1%), rehabilitation or long term care (10.1% vs 2.7%), hospice (6.8%/4.1%) and death (27.3%/8.1%) reflecting that less well patients tended to be cared for within the specialist ward.
Conclusions
Balancing the optimal location and nursing skill set is a challenge and remains an important focus and priority within a service ranging from high dose chemotherapy administration for curative intent to palliative and terminal care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont Hospital Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract